ArticleDiscover oncology2025
Prediction model for the early recurrence of stage IA-IIA non-small cell lung cancer based on hematological indexes and imaging features.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Cumulative high-risk surgical and pathologic features predict recurrence after resection of early-stage node-negative non-small cell lung cancer.JTCVS open · 2026Article
- Peripheral blood T-lymphocyte subsets provide prediction of early postoperative recurrence in elderly patients with lung cancer: model development and external validation.Frontiers in oncology · 2026Article
- Imaging features and clinical markers for predicting postoperative recurrence in early-stage lung cancer.American journal of cancer research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSome patients with non-small cell lung cancer (NSCLC) experience early relapse within 2 years post-surgery. Screening patients who are prone to recurrence is crucial. This study aimed to determine factors influencing early recurrence within 2 years of surgery for stage IA-IIA NSCLC and to establish a prediction model.
methodsWe retrospectively analyzed the hematological indices and imaging indicators of patients with stage IA-IIA NSCLC who underwent surgery at our hospital, and relevant clinical data were obtained through long-term follow-up from September 2019 to September 2020. Least absolute shrinkage and selection operator (LASSO) regression and univariate and multivariate Cox regression analyses were used to identify high-risk factors influencing postoperative recurrence, establish a predictive model, and construct a nomogram associated with recurrence-free survival.
resultsAmong 186 patients (90 male and 96 female), 29 (15.6%) experienced recurrence or metastasis during the follow-up period. Univariate analysis identified several significant factors, including tumor size, direct bilirubin, indirect bilirubin, albumin, globulin, serum creatinine, platelet-lymphocyte ratio, lymphocyte-monocyte ratio, prognostic nutrition index, albumin-alkaline phosphatase ratio, marginal lobulation, air bronchogram sign, pathological type of squamous cell carcinoma, tumor stage IB, and solid nodules. LASSO regression was used to further select variables and construct a multivariate Cox model showing globulin levels, air bronchogram signs, and solid nodules as independent prognostic factors for early recurrence within 2 years in patients with stage IA-IIA NSCLC. The Cox model stratified patients into high- and low-risk groups and was validated by Kaplan-Meier survival analysis, which demonstrated that high-risk patients had a significantly lower survival rate than low-risk patients, demonstrating the robust discriminative power of the predictive model.
conclusionGlobulin content, air bronchogram signs, and solid nodules were independent prognostic factors for early recurrence within 2 years in patients with stage IA-IIA NSCLC. The proposed model, developed based on the above factors and the albumin-alkaline phosphatase ratio, can effectively predict recurrence risk, potentially aiding clinicians in quantifying prognostic risk, making personalized survival assessments, and devising the most effective treatment plans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.